Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on ORIC Pharmaceuticals (NASDAQ:ORIC) and maintained a $20 price target.
August 13, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating on ORIC Pharmaceuticals and maintained a $20 price target.
The reiteration of an Outperform rating and a maintained price target of $20 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100